Memory Clinic Inc — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$294,865	23
2024	Research	$183,113	13
2023	Research	$189,962	13
2022	Research	$65,452	5
2021	Research	$1,718	4
2019	Research	$121,795	2

Breakdown

Who paid Research payments · program years 2019–2025

Janssen Research & Development, LLC $728,578 50 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $119,295 1 payment
Eli Lilly and Company $7,872 8 payments
Novartis Pharmaceuticals Corporation $1,160 1 payment

Studies the money was for Research payments · program years 2019–2025

A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease $594,308 46 payments
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $134,270 4 payments
PoCC dose finding in Mild to Moderate AD $119,295 1 payment
A Randomized Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $3,104 2 payments
A Randomized, Double-Blind, Delayed-Start Study of Ly3314814 Azd3293 in Early Alzheimer's Disease Dementia Extension of Study Azes, the Amaranth Study $2,500 1 payment
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $1,269 2 payments
A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $1,160 1 payment
A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $866 1 payment
A Randomized, Phase 3, Open Label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With Or Without Metformin (Surpass 6) $133 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.